Literature DB >> 7646524

Receptor-mediated toxicity to pericytes of advanced glycosylation end products: a possible mechanism of pericyte loss in diabetic microangiopathy.

S Yamagishi1, C C Hsu, M Taniguchi, S Harada, Y Yamamoto, K Ohsawa, K Kobayashi, H Yamamoto.   

Abstract

The influence of advanced glycosylation end products (AGE) on bovine retinal pericytes was investigated. When pericytes were cultured with AGE-bovine serum albumin (BSA), pericyte growth was significantly retarded in a dose-dependent manner. They also exhibited an immediate toxicity to pericytes. However, MRC-5 human fibroblasts were totally resistant to AGE-BSA. Moreover, antisense oligonucleotides complementary to mRNA coding for AGE receptor were found to reverse the AGE-induced decrease in viable pericyte number, although the mRNA level was about one order of magnitude lower in pericytes than in the fibroblasts. These results indicate that pericytes may possess a peculiar sensitivity to AGE, and that AGE ligand-receptor interactions may play an important role in the pathogenesis of pericyte loss, the principal change in diabetic microangiopathies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7646524     DOI: 10.1006/bbrc.1995.2185

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  18 in total

1.  Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury.

Authors:  Hideto Yonekura; Yasuhiko Yamamoto; Shigeru Sakurai; Ralica G Petrova; Md Joynal Abedin; Hui Li; Kiyoshi Yasui; Masayoshi Takeuchi; Zenji Makita; Shin Takasawa; Hiroshi Okamoto; Takuo Watanabe; Hiroshi Yamamoto
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

Review 2.  Trends in advanced glycation end products research in diabetes mellitus and its complications.

Authors:  José D Méndez; Jianling Xie; Montserrat Aguilar-Hernández; Verna Méndez-Valenzuela
Journal:  Mol Cell Biochem       Date:  2010-03-23       Impact factor: 3.396

3.  Diabetes-related microvascular and macrovascular diseases in the physical therapy setting.

Authors:  W Todd Cade
Journal:  Phys Ther       Date:  2008-09-18

4.  Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats.

Authors:  A W Stitt; Y M Li; T A Gardiner; R Bucala; D B Archer; H Vlassara
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

5.  Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice.

Authors:  Y Yamamoto; I Kato; T Doi; H Yonekura; S Ohashi; M Takeuchi; T Watanabe; S Yamagishi; S Sakurai; S Takasawa; H Okamoto; H Yamamoto
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

6.  SOCS3 overexpression inhibits advanced glycation end product-induced EMT in proximal tubule epithelial cells.

Authors:  Lin Yu; Ying Zhang; Huimin Zhang; Yingtao Li
Journal:  Exp Ther Med       Date:  2017-04-04       Impact factor: 2.447

Review 7.  The role of O-GlcNAc signaling in the pathogenesis of diabetic retinopathy.

Authors:  Richard D Semba; Hu Huang; Gerard A Lutty; Jennifer E Van Eyk; Gerald W Hart
Journal:  Proteomics Clin Appl       Date:  2014-02-19       Impact factor: 3.494

8.  Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells.

Authors:  Keiko Iwamoto; Keishi Kanno; Hideyuki Hyogo; Sho-Ichi Yamagishi; Masayoshi Takeuchi; Susumu Tazuma; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2008-05-06       Impact factor: 7.527

9.  Glycation, oxidation, and lipoxidation in the development of the complications of diabetes: a carbonyl stress hypothesis.

Authors:  Timothy J Lyons; Alicia J Jenkins
Journal:  Diabetes Rev (Alex)       Date:  1997

10.  PEDF in diabetic retinopathy: a protective effect of oxidative stress.

Authors:  Xiao-feng Zhu; Hai-dong Zou
Journal:  J Biomed Biotechnol       Date:  2012-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.